Propanc Biopharma reports 90% tumor growth inhibition in pancreatic cancer models

Propanc Biopharma (PPCB) says its PRP produced 90% tumor growth inhibition in pancreatic cancer models, contrasting its profile with Revolution Medicines’ daraxonrasib.